Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-DC-CTL
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
AAV-DC-CTL is an autologous cell-based immunotherapy developed by Tianjin Medical University Cancer Institute and Hospital for the treatment of advanced (Stage IV) gastric cancer. The therapy utilizes a recombinant adeno-associated virus (AAV) vector to deliver the carcinoembryonic antigen (CEA) gene into a patient's dendritic cells (DCs) ex vivo. These engineered DCs are then used to stimulate and expand antigen-specific cytotoxic T lymphocytes (CTLs) from the patient's own immune system. When re-infused into the patient, these activated CTLs are programmed to recognize and eliminate tumor cells expressing CEA, a glycoprotein often overexpressed in gastric malignancies. This approach combines gene therapy and cellular immunotherapy to enhance the body's natural anti-tumor response.
- Other names
- Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA geneCEA-targeted AAV-DC-CTL
02
Targets
Carcinoembryonic antigen peptide-HLA class I complex
Beyond the preview
Go deeper on AAV-DC-CTL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-DC-CTL.